In Vitro Drug Sensitivity Testing of Fresh Human Samples (ESAAC)
Myeloproliferative Disorders, Lymphoproliferative Disorders
About this trial
This is an interventional other trial for Myeloproliferative Disorders focused on measuring Hematological malignancies, lymphoid, myeloid, multiple myeloma, anticancer drugs, sensitivity, new treatments
Eligibility Criteria
Inclusion Criteria:
- Index cases: patients with myeloproliferative or lymphoproliferative disorders.
- Controls: patients without hematological disease, without chemotherapy ((≤ 5 years.) and without immunosuppressive treatment at the study time.
- Age ≥ 18 y.o for all the patients
Exclusion Criteria:
- Age < 18 y.o
- Pregnant or breastfeeding woman
- Patients deprived of their liberty by judicial or administrative decision.
Sites / Locations
- Centre Hospitalier Lyon Sud -Service d'Hématologie
- Centre Hospitalier Lyon Sud -Service de médecine du vieillissement
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Sham Comparator
Experimental
Lymphoproliferative disorders
Control group
Myeloproliferative disorders
Patients followed in the haematology unit of Hospices Civils de Lyon for lymproliferative disorders as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) .
Patients followed in the medicine of aging unit in the Hospices Civils de Lyon without haematological malignancies, without chemotherapy and without immunosuppressive treatment (≤ 5 years)
Patients followed in the haematology unit of Hospices Civils de Lyon for myeloproliferative disorders as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).